CRISPR Therapeutics (CRSP) Stock Forecast & Price Target

CRISPR Therapeutics is expected to yield positive results from their collaborations and product expansions, including Casgevy for sickle-cell diseases and beta-thalassemia, as well as potential treatments for Type 1 diabetes and alpha-1 antitrypsin deficiency. Despite potential risks, the company's successful gene editing technology and promising animal model results showcase strong potential for future growth and innovation. With a projected market cap of $10.82 billion and price target of $110 per share, CRISPR is poised for success in the gene editing industry.

CRISPR Therapeutics is a gene editing company with a negative outlook due to the expected commercial friction for its first approved drug, CASGEVY, and based on the slow early ramp, the stock may not be sensitive to uptake. Additionally, the company's one shot cure, CTX340, had limited effect on arterial pressure in rats, and while AGT reductions were replicated in healthy NHPs, repeat dosing resulted in no hyperkalemia or hypotension. Furthermore, although CRISPR developed Factor XI siRNA, subcu CTX611, for thromboembolic disorders, no hyperkalemia or hypotension was observed. There is still hesitation on CTX611 due to the short duration and required dose frequency.